Jason Wallace of Top Mark Health Partners lays out the investment case around minimal residual disease (MRD) testing — the blood-based technology that detects tumor DNA shed into the bloodstream, catching cancer recurrence months earlier than a scan and at extraordinarily low concentrations.
In this concise talk from The Intellectual Investor Conference, Gary Mishuris, CFA — Managing Partner and Chief Investment Officer of Silver Ring Value Partners — reframes what it actually means to have an investing edge.
The presentation explores the psychology and behavioral patterns behind fraud, using historical and modern examples to show how perpetrators exploit cognitive biases.
Texas Pacific Land (TPL) is presented as a unique, capital-light compounder offering high-margin exposure to energy and infrastructure growth, without the risks typically associated with either.
Teva Pharmaceuticals is framed as a turnaround story—recovering from past missteps while building a future in branded and specialty drugs.
Natural Resource Partners (NRP) is pitched as a mispriced, capital-light royalty company with a near-term catalyst: a dramatic increase in dividend payouts beginning in 2026.
Legal & General is presented as a deeply undervalued, capital-light compounder with a dominant position in the Pension Risk Transfer (PRT) industry, which contributes over half of its profits.
Kaspi is positioned as Kazakhstan’s dominant “super app,” integrating payments, marketplace, and BNPL services in a single platform.
International Game Technology (IGT) is portrayed as a misunderstood, cash-generative business with durable assets and compelling upside.
AI is widely expected to disrupt Google’s search business, and the authors concede that this risk is “mostly true.” However, they argue that this disruption doesn’t matter much to the long-term investment case.